Overview
Conditions
Intellectual Property
Research
R&D Pipeline
Cobroxin
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
» View Pipeline
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Drug Discovery
» Overview
» Conditions
» Intellectual Property
» Research
» R&D Pipeline
» Cobroxin
Medical Devices
» Overview
» Conditions
» Intellectual Property
» Research
Newsroom
» Recent News
» Archives
» E-Alerts
Investor Relations
» Overview
» Stock Quote
» Presentations
» SEC Filings
Corporate Overview
» Overview
» Management Team
» Board of Directors
» Social Responsiblity
» NPC Blog
» Presentations
» Code of Ethics
Contact
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.
Research
Cobratoxin inhibits pain-evoked discharge of neurons in thalamic parafascicular nucleus in rats: Involvement of cholinergic and serotonergic systems
Alpha cobratoxin as a Possible Therapy for Multiple Sclerosis: A Review of the Literature leading to Its Development for This Application
Analgesic effects of receptin, a chemically modified cobratoxin from Thailand cobra venom
Amelioration of acute and relapsing stages of the Experimental Allergic Encephalomyelitis by Cobra Toxins
A long-form a-neurotoxin from cobra venom produces potent opioid-independent analgesia
A short-chain a-neurotoxin from Naja najaatra produces potent cholinergic-dependent analgesia
Select a Destination
Drug Discovery
Medical Devices
Newsroom
Investor Relations
Corporate Overview
March 11, 2010
Nutra Pharma to Exhibit at the 12th IDGA Battlefield Healthcare Summit in Washington, D.C.
February 11, 2010
Nutra Pharma Hires David Isserman as Chief Marketing Officer
February 02, 2010
Nutra Pharma Announces Fourth Quarter Sales for its Over-the-Counter (OTC) Pain Reliever, Cobroxin
Click Here
to read the Nutra Pharma blog post entitled, "Recognizing Rare Disease Day".
Privacy Policy
|
Code of Ethics
Copyright © 2000-
2010
, Nutra Pharma Corporation. All Rights Reserved.
